Loading…
Loading…
FAST, GD, UNH, TXRH and DGX are five stocks that combine long records of uninterrupted payouts with stable earnings and solid cash flow.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for DGX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.